Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027

Published by Global Banking & Finance Review®

Posted on February 24, 2026

1 min read

Last updated: February 24, 2026

Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027 - Finance news and analysis from Global Banking & Finance Review

Tags:healthcare

Quick Summary

Novo Nordisk will lower U.S. list prices for Wegovy and Ozempic on Jan 1, 2027—up to 50% and 35%—setting a $675 monthly price. Rybelsus is included; the aim is greater affordability for patients and payers. (prnewswire.com)

Novo Nordisk to Slash U.S. List Prices for Ozempic and Wegovy in 2027

U.S. List-Price Cuts Announced for 2027

COPENHAGEN, Feb 24 (Reuters) - Danish drugmaker Novo Nordisk said on Tuesday it plans to slash the U.S. list prices of its blockbuster weight-loss drug Wegovy and diabetes drug Ozempic by up to 50% and 35% respectively as of January next year.

Drugs Affected: Ozempic and Wegovy

(Reporting by Louise Rasmussen, editing by Terje Solsvik)

Key Takeaways

•Novo Nordisk will reduce U.S. list prices for Wegovy by ~50% and Ozempic by ~35% from Jan 1, 2027, with a new $675 monthly price point. (prnewswire.com)
•The changes apply to list prices (WAC) and do not alter existing direct-to-patient self‑pay programs. (prnewswire.com)
•Rybelsus (oral semaglutide) is also included in the reset to $675 per month. (prnewswire.com)
•Move targets affordability for patients with high‑deductible or coinsurance plans and may impact payer negotiations. (prnewswire.com)
•The cuts come amid intense GLP‑1 competition, notably from Eli Lilly’s offerings. (axios.com)

Frequently Asked Questions about Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027

1What is the main topic?

Novo Nordisk plans to cut U.S. list prices for its semaglutide drugs Wegovy and Ozempic from January 1, 2027, with Wegovy down about 50% and Ozempic about 35%, to $675 per month. (prnewswire.com)

2When do the price cuts take effect and which drugs are covered?

The new list prices start January 1, 2027, and cover Wegovy, Ozempic, and Rybelsus in the U.S. market. (prnewswire.com)

3Will this lower out-of-pocket costs for all patients?

It’s designed to help patients whose costs are tied to list prices, such as those with high deductibles or coinsurance. Existing direct self‑pay programs are unchanged. (prnewswire.com)

U.S. List-Price Cuts Announced for 2027

Drugs Affected: Ozempic and Wegovy

(Reporting by Louise Rasmussen, editing by Terje Solsvik)

Key Takeaways

•Novo Nordisk will reduce U.S. list prices for Wegovy by ~50% and Ozempic by ~35% from Jan 1, 2027, with a new $675 monthly price point. (prnewswire.com)

•The changes apply to list prices (WAC) and do not alter existing direct-to-patient self‑pay programs. (prnewswire.com)

•Rybelsus (oral semaglutide) is also included in the reset to $675 per month. (prnewswire.com)

•Move targets affordability for patients with high‑deductible or coinsurance plans and may impact payer negotiations. (prnewswire.com)

•The cuts come amid intense GLP‑1 competition, notably from Eli Lilly’s offerings. (axios.com)

Frequently Asked Questions

1What is the main topic?

Novo Nordisk plans to cut U.S. list prices for its semaglutide drugs Wegovy and Ozempic from January 1, 2027, with Wegovy down about 50% and Ozempic about 35%, to $675 per month. (prnewswire.com)

2When do the price cuts take effect and which drugs are covered?

The new list prices start January 1, 2027, and cover Wegovy, Ozempic, and Rybelsus in the U.S. market. (prnewswire.com)

3Will this lower out-of-pocket costs for all patients?

It’s designed to help patients whose costs are tied to list prices, such as those with high deductibles or coinsurance. Existing direct self‑pay programs are unchanged. (prnewswire.com)